Clopidogrel (As Hydrochloride)
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Clopidogrel (As Hydrochloride) |
| DrugBank ID | DB00758 |
| Brand Names (EU) | Clopidogrel HCS |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.44% |
Approved Indication (EMA)
Secondary prevention of atherothrombotic events Clopidogrel is indicated in: Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. Adult patients suffering from acute coronary syndrome: Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutane
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | migraine with brainstem aura | 99.44% | DL |
| 2 | migraine disorder | 99.44% | DL |
| 3 | osteoarthritis | 99.25% | DL |
| 4 | tendinitis | 99.17% | DL |
| 5 | idiopathic granulomatous myositis | 99.13% | DL |
| 6 | myositis fibrosa | 99.13% | DL |
| 7 | rheumatoid arthritis | 99.03% | DL |
| 8 | osteoarthritis susceptibility | 99.01% | DL |
| 9 | pseudoachondroplasia | 98.93% | DL |
| 10 | fibromyalgia | 98.93% | DL |
| 11 | myofascial pain syndrome | 98.91% | DL |
| 12 | migraine with or without aura, susceptibility to | 98.75% | DL |
| 13 | hypoalphalipoproteinemia | 98.61% | DL |
| 14 | brachydactyly-syndactyly syndrome | 98.53% | DL |
| 15 | inclusion body myositis | 98.48% | DL |
| 16 | dermatofibrosarcoma protuberans | 98.44% | DL |
| 17 | acromesomelic dysplasia, Hunter-Thompson type | 98.40% | DL |
| 18 | intracranial embolism | 98.40% | DL |
| 19 | atrophoderma vermiculata | 98.30% | DL |
| 20 | brachyolmia | 98.29% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.